cells cultured with rapamycin (Rap, autophagy activator) treatment for 3 days, the conditioned media was harvested and used to evaluate the proliferation of Prsc cells. Quantitative PCR was used to identify cytokines secreted by Prsc cells treated with rapamycin.
INTRODUCTION AND OBJECTIVES:
Epidemiologic studies demonstrated a context between metabolic syndrome and lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Recently, preliminary evidence suggested that this connection may be imparted by the metabolic hormone ghrelin, which promoted the proliferation of prostate stromal cells in cell culture, and smooth muscle contraction of human prostate tissues in vitro. In fact, contraction and growth in the prostate are the key processes causing urethral obstruction and LUTS attributed to BPH. Here, we provide evidence suggesting that ghrelin increases prostate size in vivo, and promotes growth and contraction at genomic level.
METHODS: Ghrelin was applied (10µg/kg, i.p., 14d) to rats with testosteron-induced BPH. Prostate size was determined, and prostate tissues were subjected to microarray analysis. Expression of selected genes was analyzed for correlation with degree of BPH and ghrelin receptor (GHSR) expression in human prostate tissues and in cultured stromal cells (WPMY-1).
RESULTS: Application of ghrelin increased prostate size in rats with testosteron-induced BPH. Expression of 893 genes was analyzed by microarray in these prostates. From all genes being upregulated 2-fold or more by ghrelin in BPH rats, a role for proliferation may be assumed at least for 6 genes, a role for regulation of smooth muscle contraction at least for 12, and a role for metabolism at least for 3. These findings were verified by analysis of mRNA of 12 of these genes together with mRNA for GHSR and prostate-specific antigen (PSA) by RT-PCR in human prostate tissues. For nearly all of them (11/12), mRNA levels correlated positivley with GHSR (R>0.5). A positive correlation with PSA was only suggested for two genes. Consistently, no correlation between GHSR and PSA was evident following analysis of mRNA levels or of band intensities after Western blot analysis of human prostate tissues. Regulation of these genes by ghrelin was confirmed in WPMY-1 cells. Stimulation with the GHRS agonist MK0677 induced upregulation (1.2-fold or more) of 8 of the genes, which were upreglated by ghrelin in rat prostates and which correlated with GHSR in human prostates.
CONCLUSIONS: Ghrelin increases prostate size in BPH, and upregulates genes with a potential to promote growth or smooth muscle contraction. Ghrelin may aggravate prostate smooth muscle tone and stromal growth independent of BPH. Ghrelin regulation of prostate growth and contraction may include genomic and nongenomic mechanisms.
Source of Funding: Deutsche Forschungsgemeinschaft (DFG), Chinese Scholarship Council (CSC)
MP06-13 INHIBITION OF HUMAN PROSTATE STROMAL CELL GROWTH AND MODULATION OF CYTOSKELETAL ORGANIZATION BY LENALIDOMIDE: A NEW TREATMENT OPTION IN MALE LUTS?
Alexander Tamalunas*, Cora Sauckel, Anna Ciotkowska, Beata Rutz, Christian G. Stief, Christian Gratzke, Martin Hennenberg, Munich, Germany INTRODUCTION AND OBJECTIVES: Medical treatment in benign prostatic hyperplasia (BPH) includes reduction of prostate size to prevent disease progression, complications, and surgery, and also reduction of prostate smooth muscle tone for rapid relieve of lower urinary tract symptoms (LUTS). Combination therapies are still required to target both at once. However, current medications are insufficient, causing high rates of patient non-compliance due to an unfavourable balance between side effects and efficacy, with discontinuation rates peaking up to 90% for combination therapies. Here, we investigated the effect of lenalidomide on cellular functions including cytoskeletal organization and growth of prostate stromal cells.
METHODS: Experiments were carried out in an immortalized line of cultured human prostate stromal cells (WPMY-1). Cytoskeletal organization was visualized by phalloidin staining, while cell growth was assessed using an EdU and Colony formation assay. Cytotoxicity was addressed using CCK8.
RESULTS: Lenalidomide significantly reduced the proliferation of WPMY-1 cells. This decline was concentration-dependent, with a significantly lower proliferation rate after 72 hours of incubation. Thus, proliferation was reduced after 72 h from 64% for control to 37% and 34% for 100 and 200 µM, (p<0.01 for lenalidomide vs. control, fig. 1  A and B) . Also, colony formation was reduced after 168 h to 65% and 53% for 100 and 200 µM, respectively (p<0.01 for lenalidomide vs. control, fig. 2 A and B) . Using CCK8, no cytotoxic effects on WPMY-1 cells occurred after 72 h. In parallel, lenalidomide induced cytoskeletal disorganization: while the cellular shape of control cells was characterized by many long and thin protrusions containing bundles of actin filaments, this structure collapsed after treatment with lenalidomide ( fig. 3) .
CONCLUSIONS: Lenalidomide impairs human prostate smooth muscle growth of stromal cells, without showing cytotoxic effects. This is paralleled by a breakdown of the actin cytoskeleton, which may inhibit prostate smooth muscle contraction. Urodynamic effects in vivo appear highly possible. Functional studies as well as animal models merit further consideration.
